# Atossa Therapeutics, Inc.: Form 8-K, filed Feb 20, 2026

- Company: [Atossa Therapeutics, Inc.](/companies/atos.md) (CIK 1488039)
- Form: 8-K
- Filed: 2026-02-20
- Accepted by EDGAR: Feb 20, 2026, 16:22 ET
- Period: 2026-02-19
- Accession: 0001193125-26-061412
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/d100198d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/d100198d8k.htm

Filed Feb 20, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-061412. Last ingested by Listed: Nov 10, 2026, 17:09 ET. No prices; not investment advice.
